🔗 Share this article

While the United States proceeds with sweeping revisions to its immunization guidelines, one figure has emerged unexpectedly: Høeg, a Danish American physician and epidemiologist who first made her name by casting doubt on coronavirus shots throughout the pandemic and has focused upon possible fatalities following Covid vaccination in her recent position at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Program

Public health authorities were set to unveil major changes to the childhood vaccine schedule recently, synchronizing the US with Denmark’s immunization schedule, sources say – a major change that would put the US out of alignment with many the international standard with no evidence for public health gain. The planned update has been postponed until the coming year.

In place of Vinay Prasad, Høeg is listed to address the audience at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to run the office this calendar year.

A New Direction at the FDA

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has repeatedly called for halting certain childhood shot schedules in the US to become more in line with Denmark, a country with nationalized medicine and a population approximately the population of Wisconsin’s.

So far comments, she has continued to focus on immunizations – traditionally the domain of Prasad, director of the FDA’s vaccine center – rather than medication approval.

Doubts Over Background

The appointee has no obvious background in pharmaceutical research, approval processes or management, which has been typical for past leaders of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She lacks experience in leading a large organization. She is not an expert in drug approvals.”

Previous commissioners of the center would “grasp laws and regulations and the research of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who led the center have had.”

The drug center has an vast workload at the FDA, the former commissioner emphasized.

“The public just focuses on the innovative therapies, but the generic program authorizes numerous off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and every single one need to be looked after,” Dr. Woodcock noted. “The area you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a significant management element to the position, which manages in excess of 5,000 staff members. “It’s a massive leadership role, if you do it right,” Woodcock said.

Response and Controversial Initiatives

When asked about concerns about Dr. Høeg's fitness for the role and whether this assignment represents greater collaboration among FDA leaders on vaccines, a spokesperson responded that the “questions rely on flawed premises”.

“Her experience aligns with the responsibilities of her role,” the spokesperson explained, citing the period Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s new fast-track approval initiative, a disputed rapid drug-approval program that allegedly concerned her predecessors. “By what process are these medications being picked for this voucher program? Who is making the decisions?” Dr. Howard asked. “There is a lot of lack of transparency going on at the agency right now.”

In general, he remarked, “the Food and Drug Administration looks to be trending towards laxer regulations of all drugs, with the exception of immunizations.”

Public Past Work on Immunizations

Concerning immunizations, Høeg has a more established, if problematic, history, Howard said. She published a research paper using non-validated crowd-sourced reports to assess the rate of heart inflammation following Covid vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Among her “desired changes” for the current government included changing guidelines for recently developed shots and halting “unnecessary” immunizations, she stated following the vote on a audio program. At the FDA, Dr. Høeg has allegedly floated the idea of excluding adolescent males from receiving Covid vaccines.

“She is an all-around dogmatist who begins with her conclusions and tailors the evidence to fit the evidence in a highly disingenuous, fraudulent fashion,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|